Ideaya Biosciences Inc. (30J)

Overview

IDEAYA Biosciences, Inc. is a precision medicine oncology company with a focused approach on synthetic lethality to discover and develop targeted therapeutics. It aims to serve patient populations selected through molecular diagnostics within the United States. The company's innovative approach leverages advanced technologies and strategic alliances with major pharmaceuticals and research organizations. Founded in 2015, IDEAYA Biosciences is strategically headquartered in South San Francisco, California, positioning it at the heart of biotechnological innovation. Its collaborations span across industry leaders such as GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., along with esteemed academic institutions such as Cancer Research UK and the University of Manchester. These partnerships underscore its commitment to advancing cancer treatment through cutting-edge research and drug development.

Products and Services

• IDE196: A protein kinase C inhibitor currently under Phase 2/3 clinical trials. It targets genetically defined cancers characterized by GNAQ or GNA11 gene mutations, which are prevalent in certain melanomas and uveal melanomas.

By inhibiting the protein kinase C pathway, IDE196 aims to impede the growth of cancer cells with specific genetic mutations, providing a targeted approach to treating these aggressive cancers.

• IDE397: A methionine adenosyltransferase 2a inhibitor in Phase 1/2 clinical trials. It focuses on patients with solid tumors that have deletions in the methylthioadenosine phosphorylase gene, affecting cancers like non-small cell lung, bladder, gastric, and esophageal cancers.

IDE397's mechanism seeks to exploit the tumor's methionine dependency, potentially leading to a novel treatment avenue for these challenging solid tumor cancers.

• IDE161: A poly ADP-ribose glycohydrolase (PARG) inhibitor in Phase 1 clinical trials. It is intended for tumors characterized by homologous recombination deficiency (HRD) and other genetic or molecular signatures.

This therapeutic approach aims to exploit the vulnerability of HRD tumors to DNA damage, offering a promising direction for patients with limited treatment options.

• GSK101: In collaboration with GlaxoSmithKline, this Pol Theta helicase inhibitor is in Phase 1 clinical trial for tumors with BRCA mutations, other homologous recombination, and HRD mutations.

GSK101 explores the potential of inhibiting the DNA repair pathway in cancer cells, specifically targeting those with compromised DNA repair mechanisms for targeted cancer therapy.

• Werner Helicase inhibitors: Focused on tumors with high microsatellite instability, these inhibitors are part of the company’s preclinical research. They target a rare but critical weakness in certain cancer types.

By targeting Werner Helicase, these inhibitors aim at exploiting the unique replication stress inherent in these tumors, providing a new angle for therapeutic intervention.

In addition to these products, IDEAYA Biosciences enriches its drug discovery platform with proprietary technologies such as the DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery, the INQUIRE chemical library, and the HARMONY machine-learning engines. These innovative tools underscore the company’s leading edge in identifying and advancing novel oncology therapeutics.